DeğerQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSatış/genel/idari giderler60.8 M52.4 M43.7 M38.9 M51.1 M186.1 MAraştırma ve geliştirme9.1 M15.1 M12.5 M13.5 M12.1 M53.2 MFaaliyet karı-9.5 M49.9 M1.6 M76.5 M-27.9 M100.1 MFaaliyet Dışı Gelir, Toplam-18.1 M42.8 M-18.4 M-18.9 M-22.8 M-17.3 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)14.8 M14.7 M14.7 M15.2 M14.7 M59.3 MFaaliyet Dışı Gelir (Faiz Giderleri Hariç)-29.6 M-41.6 M-29.4 M-30.4 M-29.4 M-130.8 MOlağandışı gelirler/giderler-3.3 M69.7 M-3.7 M-3.7 M-8.1 M54.2 MVergi öncesi kar-27.6 M92.7 M-16.8 M57.6 M-50.7 M82.8 MKazançlardaki özsermayeler——————Vergiler3.7 M24.7 M-4.8 M6.4 M3.9 M30.2 MKontrol gücü olmayan/azınlık payı——————Vergi sonrası diğer gelirler/giderler-2.6 M11.3 M-2.2 M-400 K-9.1 M-400 KDurdurulan faaliyetler öncesi net kar-31.3 M68 M-12 M51.2 M-54.6 M52.6 MDurdurulan faaliyetler——————Net kar-31.3 M68 M-12 M51.2 M-54.6 M52.6 MSeyreltme ayarlaması——————İmtiyazlı temettüler——————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar-31.3 M68 M-12 M51.2 M-54.6 M52.6 MTemel hisse başına kazanç (Temel EPS)-0.551.25-0.220.96-1.010.98Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)-0.451.19-0.220.91-0.950.93Dolaşımdaki ortalama adi hisse senedi sayısı53 M54.4 M54.2 M53.2 M53.5 M215.3 MDolaşımdaki seyreltilmiş hisse senedi sayısı53 M57.3 M54.2 M56.5 M56.7 M224.7 MFAVÖK-44.5 M-65.3 M-84.5 M-22.7 M-139.4 M-311.9 MFVÖK-70.1 M-91.3 M-110 M-50.5 M-164.9 M-416.7 MGelir maliyeti—88.5 M66.9 M85.9 M84.9 M326.2 MSatılan malların diğer maliyeti——————Amortisman ve itfa (nakit akışı)26 M25.4 M23.5 M23.4 M23.5 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.